ClinicalTrials.gg
RecruitingNCT07779213FLASH AFUpdated Aug 21, 2026

Detection of Atrial Fibrillation Using PPG From Smartphone Cameras

An observational study in Atrial Fibrillation (AF), sponsored by Happitech BV. Recruiting at 5 sites in 2 countries. Open to participants aged 22 Minutes and older. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Happitech BV · Observational

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
554
Ages
22 Minutes and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 993 studies in Atrial Fibrillation with a site in United States — 161 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.

Planned enrollment
91st of 308
554 · median 200
Started
2026
with 47 others
Observational
308 of 993
59 open now
Primary completion
2026-11
later than 64 of 219 live
Registered
990th of 993
by date

Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 91st largest by planned enrollment of the 308 observational ones that give a count, is one of 48 that started in 2026, is one of 308 observational ones, reaches primary completion later than 64 of the 219 other live ones, and was the 990th registered.

Atrial Fibrillation

4,009 studies on the registry are indexed under Atrial Fibrillation; 960 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

161 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 161 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 22 Minutes and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 993 studies in Atrial Fibrillation with a site in United States, or all of them as a file.
02

Study summary

The protocol is designed to enroll patients from at least 3 diverse clinical sites with smartphones who are being evaluated for the presence or absence of atrial fibrillation (AF) using the Heart Rhythm Software algorithm running on their smartphones. Algorithm output will be compared to a gold standard of 12-lead ECG recorded with a simultaneous PPG measurement.

Read the detailed description

Atrial fibrillation (AF) is the most common sustained arrhythmia worldwide, and its prevalence is increasing and is expected to continue increasing for decades,. Detection of AF episodes may be useful for the identification of undiagnosed AF and in making clinical management decisions that include oral anticoagulation, restoration and maintenance of sinus rhythm, control of ventricular rate, and risk factor modification. Treatment of AF is associated with improvements of quality of life, stroke prevention, and reduced risk of heart failure.

Traditionally, diagnosis of AF is done using an electrocardiogram, with low amplitude or absent p-waves and narrow complex "irregularly irregular" pattern intervals seen on the ECG,. After diagnosis, there are a variety of methods that can be used to manage AF. Ambulatory ECG monitoring, implantable monitoring devices, and over-the-counter wrist-worn devices have been used to manage patients with AF,,. However, these devices are inconvenient and expensive which limits their wide adoption into clinical practice. There is an unmet clinical need for an easy to use and inexpensive over-the-counter FDA-cleared products that can detect episodes of AF in real-time and notify patients to seek out further care when AF is suspected.

Recent technological advancements have allowed for the identification of AF using smartwatches, with device manufacturers gaining over-the-counter regulatory clearance for their irregular heart rate detection algorithms,. These wrist-worn devices use a light-based measurement method called photoplethysmography (PPG) to measure changes in light absorbance and reflectance to understand changes in blood flow in superficial vasculature. The waveform generated from this measurement can be used to measure parameters like pulse rate, respiratory rate, pulse rate variability and others in addition to detecting AF. The increasing ubiquity of smartphones worldwide has led to greater availability of heart rhythm diagnostics using smartphone photoplethysmography (PPG). Smartphone camera PPG technology uses the light-emitting diode in cameras to measure pulsatile changes in light intensity that are reflected from a finger and can be used to detect AF. The widespread availability of this technology has the potential to improve the accessibility and convenience of heart rhythm monitoring, particularly in remote or underserved areas. This could result in improvements in early detection and management of AF, leading to better patient outcomes. Several smartphone PPG-based algorithms have been developed that utilize smartphones' built-in cameras to detect AF. The sensitivity and specificity of these algorithms for the detection of AF range between 81%-100% and 85%-100% respectively. However, there is a lack of evidence regarding the performance of these algorithms in detecting AF in an out-of-hospital setting using a gold-standard reference.

Happitech has developed a proprietary software development kit (SDK) that can be utilized to measure patients' cardiovascular parameters and identify potential pathologies including AF. Happitech's algorithm requires users to place a digit directly against their phone camera, and the camera and underlying algorithm detect subtle differences in blood flow to calculate physiological parameters for monitoring and clinical use.

The purpose of this study is to validate the performance of Happitech's PPG-based algorithm for the detection of AF against a 12-lead ECG in a diverse population of patients including cardiology patients being evaluated as inpatients or at a cardiology clinic visit.

03

Conditions studied

  • Atrial Fibrillation (AF)

Browse trials for

Keywords

  • wearables
  • smartphone based ppg
  • ppg
  • digital health
  • health equity
  • atrial fibrillation
  • healthtech
  • cardiac monitoring
04

Who can participate

Ages eligible
22 Minutes and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Male and female patients aged 22 years or older who are cardiology patients consulting the cardiac outpatient clinic, 50% of whom have a rhythm of atrial fibrillation at the time of enrollment, and own a smartphone.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 22 years or older
  2. Owns a smartphone and knows how to operate and navigate different applications.
  3. Individuals able to read, understand, and sign the consent form.
  4. Cardiology patients consulting the cardiac outpatient clinic.
  5. History of persistent AF or other cardiac rhythm

Exclusion criteria

Exclusion Criteria:

  1. Participants with cognitive impairments
  2. Individuals who cannot read, speak, and/or understand English
  3. Patients with implantable neurostimulators, cardiac implantable device in an atrial or ventricular paced rhythm documented on a 12-lead during the initial study visit
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
554 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Sinus Rhythm

    Patient visiting the Cardiology Clinic in Sinus Rhythm

    Diagnostic Test: 12 Lead ECG is compared to a smartphone based PPG

  • Atrial Fibrillation

    Patient visiting the Cardiology Clinic in Atrial Fibrillation

    Diagnostic Test: 12 Lead ECG is compared to a smartphone based PPG

  • Other

    Patient visiting the Cardiology Clinic with neither Sinus Rhythm or Atrial Fibrillation

    Diagnostic Test: 12 Lead ECG is compared to a smartphone based PPG

Interventions

  • Diagnostic test12 Lead ECG is compared to a smartphone based PPG

    12 Lead ECG is compared to a smartphone based PPG

06

What researchers measure

Primary outcomes

  1. To evaluate the sensitivity and specificity of the Heart Rhythm Software

    To evaluate the sensitivity and specificity of the Heart Rhythm Software algorithm running on a commercially available smartphone to detect atrial fibrillation segments using photoplethysmography (PPG) as measured through the phone's camera. Se is defined as the percentage of patients with 90 second interval recordings scored by the Heart Rhythm Software algorithm as AF, out of all intervals determined by the Clinical Adjudication Committee (CAC) to be AF (gold standard). Sp is defined as the percentage of patients with 90 second intervals scored by the Heart Rhythm Software algorithm as NSR out of all ECG recordings determined by the CAC to be NSR.

    Time frame: Through study completion, an average of 6 months

Secondary outcomes

  1. Sensitivity & Specificity across subgroups

    The accuracy of the Happitech Heart Rhythm Software algorithm in detecting irregular rhythm suspected of AF and regular rhythm suspected normal sinus rhythm will be further investigated in subgroups defined by ethnicity, race, BMI, age group, smartphone type, and Fitzpatrick scale score. The sensitivity and specificity will be presented as an estimate and associated 95% CI's, as well as a Chi-square or Fisher's Exact p-value to assess if all levels of the subgroup are homogeneous.

    Time frame: through study completion, an average of 6 months

07

Study locations

4 of 5 sites recruiting
  • Nair Research, LLC dba Arrhythmia Research Group LLC
    Jonesboro, Arkansas 72401, United States
    Recruiting
  • South Denver Cardiology
    Littleton, Colorado 80210, United States
    Recruiting
    • Kathy Siegel, Clinical Research Director · Contactksiegel@southdenver.com · 720-217-6139
    • Srikanth Sundaram, Doctor · Principal investigator
  • Tulane University
    New Orleans, Louisiana 70112, United States
    Not yet recruiting
    • Kunal Sameer, Associate Director of Ops · Contactksameer@tulane.edu · 203-285-5666
    • Nassair Marrouchi, Doctor · Principal investigator
  • CardioVascular Health Clinic
    Oklahoma City, Oklahoma 73134, United States
    Recruiting
  • Isala Zwolle
    Zwolle, Overijssel 8025 AB, Netherlands
    Recruiting
    • Fleur van Haveren, Research Cardiology · Contactf.van.haveren@isala.nl · 088 6248377
    • Sebastien Krul, Doctor · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Nov 2026, 5 months after the start.

Of 148 industry-sponsored observational studies under Atrial Fibrillation, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 42. This study's planned 5 months is below that.

Counting every sponsor, half of 698 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2026
First posted
Aug 21, 2026
StartActual
Jun 30, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07779213
Lead sponsor
Happitech BV
Responsible party
Sponsor
First posted
Aug 21, 2026
Start date
Jun 30, 2026
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Aug 21, 2026

Study contacts

Yosef Safi Harb, CEO
Contact
yosef@happitech.com
+31 (0) 681885565
Amanda Marinov, Regulatory
Contact
a.marinov@happitech.com
+359878422979

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion